These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 19341421)

  • 1. Error in calculation of indirect analyses.
    Chou R; Chan BK
    J Viral Hepat; 2009 May; 16(5):376. PubMed ID: 19341421
    [No Abstract]   [Full Text] [Related]  

  • 2. [Long-acting interferon: studies on pegylated interferon].
    Ma H; Wang H
    Zhonghua Gan Zang Bing Za Zhi; 2002 Feb; 10(1):78-9. PubMed ID: 11856520
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of hepatitis C in children.
    Aziz S
    J Coll Physicians Surg Pak; 2005 Jun; 15(6):317-8. PubMed ID: 15924831
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment with pegylated interferon and ribavirin in patients co-infected by human immunodeficiency virus and hepatitis C virus].
    Marcos Sánchez F; Albo Castaño MI; Casallo Blanco S
    Rev Clin Esp; 2007 Mar; 207(3):150-1; author reply 151-2. PubMed ID: 17397643
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatitis C treatment, HAART and side effects.
    TreatmentUpdate; 2001; 13(7):7-8. PubMed ID: 11794865
    [No Abstract]   [Full Text] [Related]  

  • 6. [HIV/HCV double infection: combination is a clear therapy option].
    Reich B
    Dtsch Med Wochenschr; 2004 Jul; 129(28-29):1590. PubMed ID: 15274242
    [No Abstract]   [Full Text] [Related]  

  • 7. Second thoughts about secondary analyses.
    Ferenci P
    Dig Liver Dis; 2005 Oct; 37(10):805-7; author reply 808-9. PubMed ID: 16023903
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatitis C drug development at a crossroads.
    Nelson DR
    Hepatology; 2009 Oct; 50(4):997-9. PubMed ID: 19787813
    [No Abstract]   [Full Text] [Related]  

  • 9. High relapse rate seen at week 72 for patients treated with R1626 combination therapy.
    Pockros P; Nelson D; Godofsky E; Rodriguez-Torres M; Everson GT; Fried MW; Ghalib R; Harrison S; Nyberg L; Shiffman ML; Chan A; Hill G
    Hepatology; 2008 Oct; 48(4):1349-50. PubMed ID: 18821613
    [No Abstract]   [Full Text] [Related]  

  • 10. [Peginterferon-alfa-2b or -alfa-2a and ribavirin combined treatment in hepatitis C infection].
    Szalay F
    Orv Hetil; 2010 Feb; 151(7):271-3. PubMed ID: 20133247
    [No Abstract]   [Full Text] [Related]  

  • 11. [Genotype 1 superresponder treat for only 24 weeks].
    MMW Fortschr Med; 2005 Dec; 147(51-52):69. PubMed ID: 16402717
    [No Abstract]   [Full Text] [Related]  

  • 12. Quality of life with pegylated interferon therapy for hepatitis C.
    Brown RS
    Hepatology; 2002 Sep; 36(3):767-8; author reply 768. PubMed ID: 12198677
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of acute hepatitis C-how to explain the differences?
    Wedemeyer H; Cornberg M; Wiegand J; Jäckel E; Manns MP
    Gastroenterology; 2006 Aug; 131(2):682-3; author reply 683-4. PubMed ID: 16890627
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of hepatitis C in HIV-coinfected patients at the CROI.
    Barreiro P
    AIDS Rev; 2004; 6(1):63. PubMed ID: 15168743
    [No Abstract]   [Full Text] [Related]  

  • 15. Interferon for hepatitis C patients with psychiatric disorders.
    Asnis GM; De La Garza R; Rego SA; Henderson MA; Reinus JF
    Am J Psychiatry; 2004 Dec; 161(12):2332; author reply 2332-4. PubMed ID: 15569920
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatitis C (chronic).
    Mohsen A; Norris S
    Clin Evid; 2006 Jun; (15):1061-72. PubMed ID: 16973044
    [No Abstract]   [Full Text] [Related]  

  • 17. Pegylated interferon-α2a versus pegylated interferon-α2b in hepatitis C: reappraisal of effectiveness on the basis of trial sequential analysis.
    Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
    Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):246-8. PubMed ID: 24366456
    [No Abstract]   [Full Text] [Related]  

  • 18. Adverse drug effects and pegylation.
    Wooten JM
    South Med J; 2011 Feb; 104(2):83-4. PubMed ID: 21206333
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment strategies of acute and chronic hepatitis C].
    Gładysz A; Inglot M
    Przegl Epidemiol; 2002; 56 Suppl 5():10-5. PubMed ID: 15553066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated interferon-alpha2a and ribavirin in HIV-hepatitis C coinfected patients.
    Expert Rev Anti Infect Ther; 2004 Jun; 2(3):341-2. PubMed ID: 15490503
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.